Halozyme Therapeutics Inc. HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Halozyme Therapeutics (NASDAQ:HALO) reported non-GAAP earnings per share (EPS) of $1.54, beating non-GAAP estimates by $0.30 and growing 69% year over year (non-GAAP). Revenue (GAAP) was $325.7 ...

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.91 per share a year ago.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of ...

Highlights,A key director reduced their stake in Halozyme Therapeutics during the past year,The transaction was executed ...